Origin: Embryonal mesenchymal-derived sarcoma mimicking immature skeletal muscle.
Molecular Subtypes:
Embryonal (80%): Favorable prognosis; head/neck, genitourinary sites.
Alveolar (15-20%): PAX3/7-FOXO1 fusions (t(2;13)/t(1;13)); poor outcome.
Pleomorphic/Spindle Cell: Rare; adult-predominant.
Genetic Predisposition: Li-Fraumeni (TP53), NF1 (↑5-fold risk).
Metric | Data |
Proportion of childhood cancers | 4-5% (most common pediatric soft-tissue sarcoma) |
Annual incidence (<15y) | 5.3/million children |
Peak ages | Bimodal: 2-6y & 15-19y |
Male:Female ratio | 1.5:1 |
Metastasis at diagnosis | 15-25% (lung, bone marrow, lymph nodes) |
Alert: 5-year survival <30% for alveolar/metastatic RMS.
Imaging:
Head/neck: MRI (↑30% soft-tissue resolution).
Whole-body: PET-CT sensitivity 92% (occult metastasis detection).
Pathology Gold Standards:
Biopsy + IHC (Myogenin+ >95%).
Molecular confirmation of PAX-FOXO1 fusion dictates therapy intensity.
Metastasis Screening:
Bone marrow biopsy + LP (40% positive in alveolar).
ctDNA monitoring (sensitivity 88%).
Risk Group | Definition | 5-yr OS |
Low-risk | Localized embryonal, complete resection | >90% |
Intermediate-risk | Locally advanced/fusion-negative alveolar | 65-75% |
High-risk | Metastatic/fusion-positive alveolar | 20-40% |
Very high-risk | Multi-organ mets/therapy resistance | <15% |
Modality | Application | Key Advances |
Surgery | Resectable tumors (e.g., paratesticular) | Secondary PRE: R0 rate ↑85% |
Radiotherapy | Positive margins/unresectable lesions | Brachytherapy: Vaginal RMS organ preservation ↑50% |
Chemotherapy | Backbone for all patients | VAC (Vincristine+Actinomycin D+Cyclophosphamide) remains standard |
Low-risk:
VAC ×1yr vs VA: 5-yr EFS 83% vs 76% (P=0.18).
Intermediate/High-risk:
Anthracycline-based (VAC+Doxorubicin): EFS ↑15%.
Maintenance (Vinorelbine+Cyclophosphamide ×12mo): ↓Relapse 32%.
Alveolar (Fusion+):
PAX-FOXO1 Targeting: MDM2 inhibitors (e.g., APG-115) + chemo → ORR ↑58%.
Therapy | Mechanism | Efficacy |
Anti-GD2 Immunotherapy | Targets GD2 ganglioside | Phase II: CR 27% (alveolar) |
CAR-T | HER2/EGFR targeting | Early trial: 1-yr OS 40% |
PARP Inhibitors | DNA damage synergy | +Chemo → PFS ↑3.8 months |
Complication | Incidence | Prevention |
Myelosuppression | 80% | G-CSF support + dose adjustment |
Cardiotoxicity | 20% | Liposomal doxorubicin (↓cardiac risk 60%) |
Neurocognitive impairment | 25% | Hippocampal-sparing RT (↑IQ retention 40%) |
Secondary Malignancies: ↑8-fold sarcoma risk in RT fields.
Fertility Preservation: Gonadal shielding → fertility >70%.
Functional Outcomes: Limb salvage >90% (neoadjuvant chemo + precision surgery).
1. Overcoming Resistance
ctDNA Monitoring: Predicts resistance (sensitivity 92%).
Epigenetic Modulation: HDAC inhibitors (Chidamide) reverse chemo-resistance.
2. Global Equity Initiatives
Africa-Adapted Protocol: Dexamethasone + Cyclophosphamide ($<300), survival ↑11%→39%.
AI-Assisted Diagnosis: Smartphone microscopy ↓misdiagnosis 60% in low-resource settings.
3. Clinical Trial Highlights
Approach | Example | Potential Benefit |
Dual-target CAR-T | CD276/EGFRvIII | ↓Relapse 50% |
Oncolytic Virus | HSV-GMCSF | ↑Local control 65% |
Peptide Vaccine | WT1-targeted | 5-yr EFS >70% |
RMS management has achieved:
1. Molecular Stratification: PAX-FOXO1 status guides precision therapy (↑survival 3-fold in high-risk).
2. Function-Preserving Approaches: Brachytherapy/limb salvage → function retention >80%.
3. Global Standardization: European guidelines unify care; 5-yr OS reaches 74.3%.
Future Imperatives: Targeting clonal evolution, reducing toxicity, and expanding global access to achieve "cure without disability."
Data Sources:
European RMS Guidelines (2022) | IRS-V Trial | PARP inhibitor studies | Global equity programs.
EN
CN